Region Oestergoetland

At Region Oestergoetland’s Department of Gastroenterology, investigators are evaluating antibiotic strategies for serious bacterial infections, including the use of kloxacillin in patients with Staphylococcus aureus bacteremia. The work aims to refine dosing and improve safety.

• Therapeutic drug monitoring of kloxacillin
• Predictive value of eGFR for dosing adjustments
• Antibiotic versus no‑antibiotic treatment for severe tonsillitis

Seven active trials involving 13 investigators focus on optimizing antimicrobial therapy and reducing treatment‑related complications.

The site is testing a novel approach to curb post‑operative atrial fibrillation and associated kidney injury after coronary artery bypass grafting using an SGLT2 inhibitor. The goal is to lower the incidence of new‑onset arrhythmia during hospital stay.

• Efficacy of dapagliflozin in preventing AF after surgery
• Impact on acute kidney injury rates
• Safety profile in cardiac surgery patients

This cardiovascular research seeks to improve postoperative outcomes and reduce readmissions.

Researchers are examining long‑term disease control in ANCA‑associated vasculitis by comparing continued rituximab therapy with treatment discontinuation. The study measures relapse rates and safety in patients who have achieved stable remission.

• Rituximab maintenance versus discontinuation
• Relapse frequency after stopping therapy
• Monitoring of adverse events over time

The trial aims to define optimal maintenance strategies for this autoimmune condition.

In the realm of bone‑related oncology, the department is conducting trials on Ewing sarcoma to assess whether adding a maintenance regimen improves event‑free survival. Radiation dose levels are also being compared for safety and effectiveness.

• Maintenance chemotherapy with VinoCyc
• High‑dose versus low‑dose radiotherapy
• Survival outcomes in localized and disseminated disease

These studies target better long‑term control of this aggressive sarcoma.

A randomized trial is evaluating whether simvastatin can delay severe liver complications, including bile‑duct cancer, variceal bleeding, and the need for transplantation in patients with primary sclerosing cholangitis.

• Prevention of cholangiocarcinoma
• Reduction of variceal bleeding episodes
• Delay of liver transplantation

The research explores repurposing a cholesterol‑lowering drug to improve outcomes in this chronic liver disease.

Ongoing investigations focus on patients with idiopathic pulmonary fibrosis and other forms of progressive pulmonary fibrosis, assessing the long‑term safety and efficacy of oral nerandomilast. The primary aim is to monitor tolerability while patients remain on therapy.

• Long‑term tolerability assessment
• Safety monitoring of adverse events
• Evaluation of disease progression markers

The study seeks to provide clearer guidance on managing fibrotic lung disease after earlier trial phases.